Format

Send to

Choose Destination
J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Author information

1
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA.

Abstract

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.

PMID:
20630094
PMCID:
PMC2917408
DOI:
10.1186/1479-5876-8-67
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center